# Expert Opinion on Drug Safety

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/expert-opinion-on-drug-safety/

## Facts

| Field | Value |
| --- | --- |
| Citations | 80,540 |
| h-index | 111 |
| Homepage | http://informahealthcare.com/journal/eds |
| Open Access | false |
| ISSN-L | 1474-0338 |
| ISSNs | 1474-0338,1744-764X |
| OpenAlex ID | https://openalex.org/S20709540 |
| Publisher | Taylor & Francis |
| Works | 3,186 |

## Journal papers

- [A systematic review of the safety of probiotics](https://scholariq.org/papers/a-systematic-review-of-the-safety-of-probiotics/)
- [Hydroxychloroquine in systemic lupus erythematosus (SLE)](https://scholariq.org/papers/hydroxychloroquine-in-systemic-lupus-erythematosus-sle/)
- [Hydroxyurea therapy for sickle cell anemia](https://scholariq.org/papers/hydroxyurea-therapy-for-sickle-cell-anemia/)
- [Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis](https://scholariq.org/papers/cardiovascular-risk-associated-with-testosterone-boosting-medications-a/)
- [Drugs with anticholinergic properties: a current perspective on use and safety](https://scholariq.org/papers/drugs-with-anticholinergic-properties-a-current-perspective-on-use-and-safety/)
- [Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use](https://scholariq.org/papers/nasal-decongestants-in-the-treatment-of-chronic-nasal-obstruction-efficacy-and/)
- [Are risk minimization measures for approved drugs in Europe effective? A systematic review](https://scholariq.org/papers/are-risk-minimization-measures-for-approved-drugs-in-europe-effective-a/)
- [Statins and their increased risk of inducing diabetes](https://scholariq.org/papers/statins-and-their-increased-risk-of-inducing-diabetes/)
- [A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015](https://scholariq.org/papers/a-descriptive-review-of-additional-risk-minimisation-measures-applied-to-eu/)
- [The safety of pharmacological treatment options for lupus nephritis](https://scholariq.org/papers/the-safety-of-pharmacological-treatment-options-for-lupus-nephritis/)
- [Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications](https://scholariq.org/papers/comprehensive-analysis-of-adverse-drug-reactions-associated-with-teduglutide/)
- [Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database](https://scholariq.org/papers/diarrhea-predominant-irritable-bowel-syndrome-treatment-options-eluxadoline/)

## Journal top topics

Showing 8 of 25.

- [Pharmacovigilance and Adverse Drug Reactions](https://scholariq.org/topics/pharmacovigilance-and-adverse-drug-reactions/)
- [Drug-Induced Adverse Reactions](https://scholariq.org/topics/drug-induced-adverse-reactions/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Pharmaceutical studies and practices](https://scholariq.org/topics/pharmaceutical-studies-and-practices/)
- [Pharmacological Effects and Toxicity Studies](https://scholariq.org/topics/pharmacological-effects-and-toxicity-studies/)
- [Pregnancy and Medication Impact](https://scholariq.org/topics/pregnancy-and-medication-impact/)
- [Schizophrenia research and treatment](https://scholariq.org/topics/schizophrenia-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.